- Home
- PSNYW vs ABEO Comparison
PSNYW vs ABEO Comparison
Compare PSNYW & ABEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PSNYW
- ABEO
- Stock Information
- Founded
- PSNYW 2017
- ABEO 1974
- Country
- PSNYW Sweden
- ABEO United States
- Employees
- PSNYW 2547
- ABEO N/A
- Industry
- PSNYW Auto Manufacturing
- ABEO Biotechnology: Pharmaceutical Preparations
- Sector
- PSNYW Consumer Discretionary
- ABEO Health Care
- Exchange
- PSNYW Nasdaq
- ABEO Nasdaq
- Market Cap
- PSNYW 316.6M
- ABEO 256.9M
- IPO Year
- PSNYW N/A
- ABEO 1980
- Fundamental
- Price
- PSNYW $0.17
- ABEO $5.69
- Analyst Decision
- PSNYW
- ABEO Strong Buy
- Analyst Count
- PSNYW 0
- ABEO 6
- Target Price
- PSNYW N/A
- ABEO $18.00
- AVG Volume (30 Days)
- PSNYW 43.4K
- ABEO 1.1M
- Earning Date
- PSNYW 03-06-2025
- ABEO 08-11-2025
- Dividend Yield
- PSNYW N/A
- ABEO N/A
- EPS Growth
- PSNYW N/A
- ABEO N/A
- EPS
- PSNYW N/A
- ABEO N/A
- Revenue
- PSNYW $2,034,261,000.00
- ABEO N/A
- Revenue This Year
- PSNYW N/A
- ABEO N/A
- Revenue Next Year
- PSNYW $79.49
- ABEO $323.51
- P/E Ratio
- PSNYW N/A
- ABEO N/A
- Revenue Growth
- PSNYW N/A
- ABEO N/A
- 52 Week Low
- PSNYW $0.09
- ABEO $3.93
- 52 Week High
- PSNYW $0.61
- ABEO $7.32
- Technical
- Relative Strength Index (RSI)
- PSNYW 67.00
- ABEO 47.54
- Support Level
- PSNYW $0.15
- ABEO $5.68
- Resistance Level
- PSNYW $0.18
- ABEO $5.93
- Average True Range (ATR)
- PSNYW 0.01
- ABEO 0.26
- MACD
- PSNYW 0.00
- ABEO -0.01
- Stochastic Oscillator
- PSNYW 69.57
- ABEO 56.25
About PSNYW Polestar Automotive Holding UK PLC Class C-1 ADS (ADW)
Polestar Automotive Holding UK PLC operates as an electric vehicle manufacturer. It engages in designing products that are engineered to excite consumers and drive change. Polestar defines market standards in design, technology, and sustainability. Polestar was established as a premium electric car brand by Volvo Cars and Geely Holdings. Polestar has produced two electric performance cars, namely Polestar 1 and Polestar 2. Geographically, it derives a majority of revenue from the United Kingdom.
About ABEO Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.